| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H38O2 |
| Molecular Weight | 382.5787 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C=C(CC[C@]34C)OC5CCCC5
InChI
InChIKey=XAVRSHOUEXATJE-FBQZJRKBSA-N
InChI=1S/C26H38O2/c1-17(27)22-10-11-23-21-9-8-18-16-20(28-19-6-4-5-7-19)12-14-25(18,2)24(21)13-15-26(22,23)3/h8,16,19,21-24H,4-7,9-15H2,1-3H3/t21-,22+,23-,24-,25-,26+/m0/s1
| Molecular Formula | C26H38O2 |
| Molecular Weight | 382.5787 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Quingestrone is a progestin, or a synthetic progestogen, patented by Laboratoires francais de chimiotherapie as an anti-inflammatory agent. Quingestrone acts as an agonist of the progesterone receptor weak glucocorticoid activity. Quingestrone was formerly used in combination with ethinylestradiol or mestranol in combined birth control pills in Italy. The medication was studied in the clinical prevention of miscarriage during pregnancy, but insufficient efficacy was observed at the dosage assessed
